How Ongoing Research Could Reshape EGFR+ NSCLC Management

Christine Lovly, MD, PhD, and Matthew Lee, MD, highlight ongoing research efforts that could further reshape the EGFR-mutated non–small cell lung cancer treatment landscape. Lovly discusses emerging therapies, including novel combinations and antibody-drug conjugates, aimed at overcoming resistance. Lee emphasizes the need for continued investigation into biomarkers and sequencing strategies to better personalize care.